10868
doi
10.1016/j.bmcl.2014.01.080
oai:zenodo.org:10868
user-inmind
user-eu
Damont, Annelaure
CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France
Peyronneau, Marie-Anne
CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France
Kuhnast, Bertrand
CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France
Bernards, Nicholas
CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France and Inserm, U1023, Université Paris Sud, Orsay, France
Pottier, Géraldine
CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, FranceCEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France and Inserm, U1023, Université Paris Sud, Orsay, France
Marguet, Frank
Exploratory Unit, Sanofi, Chilly-Mazarin, France
Puech, Frédéric
Exploratory Unit, Sanofi, Chilly-Mazarin, France
Boisgard Raphael
CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France and Inserm, U1023, Université Paris Sud, Orsay, France
Dollé, Frédéric
CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France
Preparation and evaluation of novel pyrazolo[1,5-a]pyrimidine acetamides, closely related to DPA-714, as potent ligands for imaging the TSPO 18 kDa with PET
Médran-Navarrete, Vincent
CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France
info:eu-repo/semantics/restrictedAccess
DPA-714 analogues
TSPO 18 kDa
Fluorinated ligands
Metabolism
PET imaging
<p>A series of four novel analogues of DPA-714, bearing a fluoroalkynyl side chain (with a length ranging from three to six carbon atoms) in replacement of the fluoroethoxy motif, have been synthetized in six steps from commercially available methyl 4-iodobenzoate. The synthetic strategy for the preparation of these N,N-diethyl-2-(2-(4-(x-fluoroalk-1-ynyl)phenyl)-5,7 dimethylpyrazolo[1,5-a]pyrimidin-3- yl)acetamides (7a–d) consisted in derivatizing a key iodinated building block featuring the pyrazolopyrimidine acetamide backbone of DPA-714, by Sonogashira couplings with various alkynyl reagents. The resulting alkynols were subsequently fluorinated, yielding the expected target derivatives. All four analogues exhibited slightly higher affinity and selectivity towards the TSPO 18 kDa (Ki vs [3H]PK11195: 0.35–0.79 nM; Ki vs [3H]flunitrazepam: >1000 nM) when compared to DPA-714 (Ki vs [3H]PK11195: 0.91 nM; Ki vs [3H]flunitrazepam: >1000 nM). Lipophilicities (HPLC, logD7.4) increased with the chain length (from 3.6 to 4.3) and were significantly higher than the one determined for DPA-714 (2.9). Preliminary in vitro metabolism evaluation using rat microsomal incubations and LC–MS analyses showed, for all four novel analogues, the absence of defluorinated metabolites. Among them, the fluoropentynyl compound, DPA-C5yne (7c), was selected, labelled in one single step with fluorine-18 from the corresponding tosylate and in vivo evaluated with PET on our in-house-developed rat model of acute local neuroinflammation.</p>
Zenodo
2014-02-07
info:eu-repo/semantics/article
605229
user-inmind
user-eu
award_title=Imaging of Neuroinflammation in Neurodegenerative Diseases; award_number=278850; award_identifiers_scheme=url; award_identifiers_identifier=https://cordis.europa.eu/projects/278850; funder_id=00k4n6c32; funder_name=European Commission;
1579532207.251212
public
Bioorg Med Chem Lett.
24
6
1550-6
2014-02-07